1-(3-吡啶基)-3-(二甲氨基)-2-丙烯-1-酮是一类重要的有机合成反应中间体,广泛应用于医药、天然产物及功能材料等诸多领域。
医药; 天然产物; 功能材料
合成路线 1（1. 合成：55314-16-4）
产率：92%
合成条件：at 90 - 95℃; for 2 h;
实验步骤：实施例-2：3-二甲基氨基-1-吡啶-3-基丙烯酮的制备方法A：加热3-乙酰基吡啶（25g，0.20mol），N，N-二甲基甲酰胺二甲基缩醛（37g，0.31mol）和乙酸（2.5ml） 在90-95℃下连续2小时，连续除去甲醇。 反应完成后，在真空下蒸馏出反应中形成的过量甲醇。 将所得残余物用水稀释并用二氯甲烷（125ml）萃取。 用水洗涤有机层并在真空下完全蒸馏出，得到34g（92％）标题化合物，HPLC纯度为99.1％。
参考文献：
- [1] Synlett, 2016, vol. 27, # 15, p. 2233 - 2236 [2] RSC Advances, 2018, vol. 8, # 47, p. 26828 - 26836 [3] Molecules, 2009, vol. 14, # 10, p. 4166 - 4179 [4] Patent: WO2011/39782, 2011, A1. Location in patent: Page/Page column 14 [5] Organic Process Research and Development, 2008, vol. 12, # 3, p. 490 - 495 [6] Dalton Transactions, 2014, vol. 43, # 35, p. 13299 - 13306 [7] Patent: US9095622, 2015, B2. Location in patent: Page/Page column 31 [8] Chemical Communications, 2010, vol. 46, # 14, p. 2450 - 2452 [9] Journal of Medicinal Chemistry, 2008, vol. 51, # 14, p. 4072 - 4075 [10] Bioorganic and Medicinal Chemistry, 2014, vol. 22, # 1, p. 623 - 632 [11] Patent: EP3287456, 2018, A1. Location in patent: Paragraph 0070 [12] Bioorganic and Medicinal Chemistry, 2010, vol. 18, # 11, p. 3860 - 3874 [13] Heterocycles, 2014, vol. 89, # 3, p. 693 - 708 [14] European Journal of Medicinal Chemistry, 2011, vol. 46, # 12, p. 5817 - 5824 [15] Organic and Biomolecular Chemistry, 2009, vol. 7, # 24, p. 5129 - 5136 [16] Angewandte Chemie - International Edition, 2013, vol. 52, # 33, p. 8551 - 8556 [17] Angew. Chem., 2013, vol. 125, # 33, p. 8713 - 8718,6 [18] Journal of the Korean Chemical Society, 2011, vol. 55, # 2, p. 243 - 250 [19] Asian Journal of Chemistry, 2012, vol. 24, # 4, p. 1837 - 1843 [20] Patent: US2008/300268, 2008, A1. Location in patent: Page/Page column 50; 59 [21] Journal of Medicinal Chemistry, 2005, vol. 48, # 1, p. 249 - 255 [22] Patent: US2004/248918, 2004, A1. Location in patent: Page 6 [23] Chemical Communications, 2010, vol. 46, # 7, p. 1118 - 1120 [24] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, # 17, p. 5232 - 5236 [25] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, # 21, p. 6282 - 6285 [26] Patent: WO2011/49150, 2011, A1. Location in patent: Page/Page column 287-288 [27] Journal of the American Chemical Society, 2012, vol. 134, # 1, p. 700 - 706 [28] Synthetic Communications, 2012, vol. 42, # 10, p. 1521 - 1531 [29] Organic Letters, 2012, vol. 14, # 15, p. 3920 - 3923 [30] Patent: WO2015/87343, 2015, A2. Location in patent: Page/Page column 15 [31] Journal of Heterocyclic Chemistry, 2015, vol. 52, # 5, p. 1296 - 1301 [32] Journal of Organic Chemistry, 2016, vol. 81, # 23, p. 11788 - 11801 [33] European Journal of Medicinal Chemistry, 2017, vol. 128, p. 1 - 12 [34] Archiv der Pharmazie, 2017, vol. 350, # 3-4, [35] Journal of Molecular Structure, 2018, vol. 1171, p. 541 - 550 [36] Patent: WO2008/130944, 2008, A1. Location in patent: Page/Page column 15-16 [37] Patent: WO2008/137770, 2008, A1. Location in patent: Page/Page column 26 [38] Patent: WO2008/137794, 2008, A1. Location in patent: Page/Page column 27 [39] Patent: WO2008/137605, 2008, A1. Location in patent: Page/Page column 26
